Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine Augmentation in Severe OCD
NCT00254735Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing Quetiapine Augmentation with Placebo Control (2 arms). Primary endpoint: Yale-Brown Obsessive Compulsive Scale. Started Apr 2002; status: completed.
02
Drugs
quetiapine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT00254735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00254735.